Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Hearing Aids to Reach Millions With FDA Over-the-Counter Approval

(Bloomberg Law) — Nearly 30 million US adults impacted by hearing loss will now have easier access to hearing aids under a final rule from the FDA allowing them to be purchased over the counter. The action, which finalizes an October 2021 draft rule, would establish a separate medical device category for certain air-conduction hearing…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Hearing Aids to Reach Millions With FDA Over-the-Counter Approval

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

(Bloomberg Law) — Nearly 30 million US adults impacted by hearing loss will now have easier access to hearing aids under a final rule from the FDA allowing them to be purchased over the counter.

The action, which finalizes an October 2021 draft rule, would establish a separate medical device category for certain air-conduction hearing aids used among people 18 years old and older with mild to moderate hearing issues. The new rule stems from President Joe Biden‘s sweeping mandate to crack down on monopolistic practices in agriculture, technology, pharmaceuticals, and other industries. Biden’s order instructed the FDA to take actions within 120 days that would allow hearing aids to be sold over the counter.

“Hearing loss is a critical public health issue that affects the ability of millions of Americans to effectively communicate in their daily social interactions,” FDA Commissioner Robert M. Califf said in a statement. “Establishing this new regulatory category will allow people with perceived mild to moderate hearing loss to have convenient access to a wide array of safe, effective, and affordable purchasing options from their neighborhood store or online.”

The FDA, along with the final rule, issued guidance differentiating between hearing aids and personal sound amplification products, which help people with normal hearing ability amplify sounds in certain environments. Hearing aids are regulated as medical devices by the FDA, unlike sound amplification products, whose manufacturers aren’t subject to product registration requirements.

The 2017 FDA user fee reauthorization included provisions for the FDA to conduct rulemaking to establish an over-the-counter category for hearing aids. The bipartisan legislation also called for the agency to establish safety and effectiveness requirements for products that fall in this category.

Califf said in a call with reporters Tuesday that only about one-fifth of Americans who experience hearing loss seek intervention with the help of hearing aids or other care, due in part to their high costs and the stigma of being perceived as old or disabled. The FDA estimates that the introduction of more over-the-counter hearing aids could lead to roughly $2,800 in savings per pair. Americans currently looking to acquire these products may have to pay up to $5,000 per pair, according to the agency.

In addition to reducing costs for patients, the final rule will “unleash new innovation, which ultimately will mean better quality products and lower prices,” Brian Deese, the White House Director of the National Economic Council, said in Tuesday’s call.

The final rule will take effect in 60 days, and Americans could start seeing over-the-counter hearing aids available at drug and retail stores as soon as mid-October, the FDA said.

Maintaining Safety

The FDA received more than 1,000 comments on the 2021 proposed rule. The Hearing Industries Association told the agency that strict safety and efficacy standards were needed for over-the-counter hearing aids because since 2017, products have entered the market that were “ineffective, of poor quality, and in some cases, dangerous.”

The final rule includes several changes based on the public comments it received, including lowering the maximum sound output of over-the-counter devices to reduce the risk of sound overamplification. It also includes a revised limit to the depth the device can reach in the ear canal, and requires that all hearing aids sold over the counter include a user-adjustable volume control.

The action from FDA is “a significant step forward for the millions of Americans who suffer hearing loss yet are untreated,” HIA President Kate Carr said in a press release. “Hearing loss is unique to each person, and most do not know if their condition is mild, moderate, or greater, caused by another medical issue or something as simple as ear wax.”

“HIA supports the final rule and recommends that the best treatment for hearing loss involves seeing a hearing professional,” Carr added.

The FDA said in its rule that over-the-counter hearing aids will limit cost and medical visit barriers for many, but that it “is not suggesting that licensed persons or their professional services are unimportant or not valuable.”

“We recommend consulting licensed persons in several circumstances, including for the diagnosis of hearing impairment and in the fitting and continued use of OTC hearing aids when consumers choose to seek such services,” the agency said.

Driving Competition

Biden administration officials and policy analysts say the final rule will improve barriers to competition that will benefit both industry and consumers.

Many Americans with mild to moderate hearing impairment have traditionally needed prescriptions from a licensed provider to get a hearing aid, which Deese said Tuesday served as a “barrier to entry” that “kept more companies, or more innovators, from entering the market to compete.”

“That not only limited who could enter the market and get distribution, but the bundling of hearing aids with exams also reduced competition by making it harder for consumers to comparison shop for the best deal,” he added.

Medicare doesn’t cover the costs of hearing aids, or exams for fitting the aids. This has made hearing aids less desirable among many who could benefit from them.

“Hearing aids for the vast majority of Americans are a complete out of pocket expense,” Frank Lin, director of the Johns Hopkins University Cochlear Center for Hearing and Public Health, said in an interview. He added that the FDA in its final rule “struck the right balance” between “fostering safety while ensuring efficacy,” and allowing innovation and competition.

Sens. Elizabeth Warren (D-Mass.) and Chuck Grassley (R-Iowa), who together introduced the Over-the-Counter Hearing Aid Act that Congress passed with user fee reauthorization legislation in 2017, said in a joint statement Tuesday that they’re “thrilled that the FDA has finalized these guidelines.”

“Safe, effective, accessible and affordable hearing aids will now be available over-the-counter for millions of Americans,” they said.

To contact the reporter on this story: Celine Castronuovo at ccastronuovo@bloombergindustry.com

To contact the editors responsible for this story: Cheryl Saenz at csaenz@bloombergindustry.com; Alexis Kramer at akramer@bloomberglaw.com

More stories like this are available on bloomberg.com.

©2022 Bloomberg L.P.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Health systems are partnering up without changing who owns the hospital

Health systems are partnering up without changing who owns the hospital

Health systems are choosing alliances over mergers, per a July McDermott Will & Schulte analysis and four July deals tracked by Becker's Hospital Review. St. Christopher's, Nemours, Jefferson and Temple signed a nonbinding alliance letter; Palomar UC San Diego Health launched July 1. Ownership stays put; governance, purchasing and outpatient investment absorb the change.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Telemedicine in eye care stops at the retinal scan unless imaging moves home

Telemedicine in eye care stops at the retinal scan unless imaging moves home

An Ophthalmology Times commentary by T.Y. Alvin Liu, Ferdinand Hui and Phillip Phan sorts eye patients into three telemedicine tiers by clinical need. Patients needing regular OCT scans benefit less unless a home device can send the image. Video tools already sit inside Epic and Cerner; the deciding purchase for retina clinics is the imaging device in the patient's living room.

  • 01The dividing line for eye telemedicine is imaging, not video: patients who need regular OCT scans benefit less from remote visits unless a device at home can send the scan, so a video license alone shifts few of those encounters.
  • 02The provider-side requirement, a HIPAA-compliant secured video platform, was already built into Epic and Cerner by 2020; the patient-side requirements (1.5 MB up and down bandwidth, a quiet private room, comfort with the technology) sit outside the health system's control and are the ones worth screening for at scheduling.
  • 03Self-administered home color fundus photography for tracking non-proliferative diabetic retinopathy was named as the nearer route into retina telemedicine; home OCT for wet AMD is the harder gate and the device to watch.

Sep 19, 2026

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Value-based care reaches a quarter of revenue at 30% of surveyed health organizations

Wolters Kluwer Health argues value-based care software is judged on whether customers hit incentive thresholds and avoid penalties. A Fierce Healthcare-reported survey it cites puts value-based care at a quarter or more of revenue for 30% of organizations. The analysis is a vendor publication that ends by pitching its own UpToDate Connect API.

  • 01The sharper question for any population health or care coordination platform is whether it changes what a clinician does at the moment of decision, or only reports afterward what happened. Wolters Kluwer's reading of the evidence is that many platforms still struggle with the first.
  • 02Vendors selling into value-based contracts now face a build-or-license decision on clinical content, because Wolters Kluwer names current, trusted content, consistent clinician adoption across sites, and a traceable link from guidance to quality metrics as the three hard problems.

Sep 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512